Arbutus Reports Second Quarter 2020 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Arbutus Biopharma (ABUS) Misses Q2 EPS by 1c
August 7, 2020 7:42 AM EDTArbutus Biopharma (NASDAQ: ABUS) reported Q2 EPS of ($0.25), $0.01 worse than the analyst estimate of ($0.24). Revenue for the quarter came in at $1.51 million versus the consensus estimate of $1.74 million.
William Collier, President and Chief Executive Officer of Arbutus, stated, Despite the challenging conditions... More
